Elan Strikes $1 Billion Royalty Deal with Theravance

13.05.2013 - Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21% of the royalties that U.S. company Theravance receives from GlaxoSmithKline for...